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Although fish and seafood are well known for their nutritional benefits, they contain contaminants 
that might affect human health. Organic lipid-soluble arsenic species, so called arsenolipids, belong 
to the emerging contaminants in these food items; their toxicity has yet to be systematically studied. 
Here, we apply the in vivo model Caenorhabditis elegans to assess the effects of two arsenic-
containing hydrocarbons (AsHC), a saturated arsenic-containing fatty acid (AsFA), and an arsenic-
containing triacylglyceride (AsTAG) in a whole organism. Although all arsenolipids were highly 
bioavailable in Caenorhabditis elegans, only the AsHCs were substantially metabolized to thioxylated 
or shortened metabolic products and induced significant toxicity, affecting both survival and 
development. Furthermore, the AsHCs were several fold more potent as compared to the toxic 
reference arsenite. This study clearly indicates the need for a full hazard identification of subclasses 




Arsenolipids represent a large group of various organic lipophilic arsenic species occurring in marine 
fish, seafood, algae1–6, and freshwater fish7. Based to their chemical structure, arsenolipids are 
grouped into several subclasses. Among others, arsenic-containing hydrocarbons (AsHCs), arsenic-
containing fatty acids (AsFAs), and arsenic-containing triacylglycerides (AsTAGs)5,8–11 represent 
three food relevant arsenolipid classes, with algae, fish, and shellfish being the food items 
contributing the majority of human arsenolipid exposure12. 
Whereas the toxicity of the human carcinogen inorganic arsenic (iAs) has been extensively 
characterized, available studies for arsenolipids are rare. After ingestion of cod liver oil, arsenolipids 
are metabolized in humans, with dimethylarsinic acid (DMAV) being a major urinary metabolite13. In 
human liver, bladder and neurons, AsHCs exert toxic effects in a similar concentration range as 
arsenite (iAsIII), however, their toxic modes of action seem to differ14–19. Moreover, AsHCs are 
likely to cross physiological barriers among others the intestinal as well as brain barriers15,16,20,21. 
In contrast, AsFAs are less toxic as compared to iAsIII and AsHCs in human liver cells22 and are 
unlikely to get transferred as intact AsFAs across the intestinal barrier21. There have been no 
toxicological studies on AsTAGs.  
In this study the in vivo model organism Caenorhabditis elegans (C. elegans) combined with 
advanced analytical techniques were applied to compare the toxicity, bioavailability and metabolism 
of two AsHCs, an AsFA and an AsTAG as well as iAsIII (Figure 1) in a whole organism. C. elegans is an 
optimal model as it is less complex compared to mammalian systems and it is easy to handle. 60 – 
80% of human genes have homologous genes in C. elegans and metal homeostasis and transport is 
conserved 23. Because of their small size, short life-cycle (about 3 days) and high ability to 
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Abbreviations  
AsFA  arsenic-containing fatty acid 
AsHC  arsenic-containing hydrocarbon 
AsTAG  arsenic-containing triacylglyceride 
DMAV  dimethylarsinic acid  
DMAB   dimethylarsenobutanoic acid 
DMAPr  dimethylarsenopropanoic acid  
iAsIII  arsenite 
 
Highlights 
• AsHCs and AsTAG are highly bioavailable to C. elegans 
• AsHCs are metabolized by C. elegans 
• AsHCs but not AsTAG and AsFA affect survival and development in C. elegans 
  
Figure 1: Chemical structure of 1-(dimethylarsinyl)pentadecane (AsHC 332); 1-
(dimethylarsinyl)heptadecane (AsHC 360), 15-(dimethylarsinyl)pentadecanoic acid (AsFA 362), 2-((15 
(dimethylarsinoyl)-pentadecanoyl)oxy)propane-1,3-diyl dipalmitate (AsTAG 912), and arsenite 
(iAsIII). 
Experimental 
C. elegans and handling 
The N2 Bristol strain (wild type) was obtained from the Caenorhabditis Genetics Center (CGC, 
University of Minnesota). The worms were propagated at 20 °C either on Nematode Growth 
Medium (NGM) or 8 P plates seeded with Escherichia coli strains OP50 or NA22, as described 
previously26, by isolating embryos from gravid worms using a bleaching solution (1% NaOCl and 0.25 
M NaOH), and allowing these embryos to hatch in M9 buffer for 18 h. Synchronous L1 populations 
were obtained and used for the experiments. 
Preparation of standard solutions 
Synthesis and purification of the two arsenic-containing hydrocarbons (AsHC 332, 1-
(dimethylarsinyl)pentadecane; AsHC 360, 1-(dimethylarsinyl)heptadecane), the arsenic-containing 
fatty acid (AsFA 362, 15-(dimethylarsinyl)pentadecanoic acid) and the arsenic-containing 
triacylglyceride (AsTAG 912, 2-((15-(dimethylarsinoyl)pentadecanoyl)oxy)propane-1,3-diyl 
dipalmitate) was carried out as described before8,27. The purity of the compounds (>98%) was 
established by NMR spectroscopy and HPLC/mass spectrometry stock solutions of the respective 
AsHCs, AsFA, and AsTAG were prepared in 100% EtOH (Carl Roth GmbH + Co KG, Karlsruhe, 
Germany) with a final concentration of 10 mM and stored at 4 °C28; additional dilutions were 
prepared shortly before each experiment with EtOH. For all experiments with lipid-soluble 
arsenicals, the final EtOH concentration was set to a constant level of 1%, which did not induce any 
toxic effects (data not shown). Stock solution of the water-soluble compound iAsIII (Sigma-Aldrich 
Chemie GmbH, Steinheim, Germany, 99% purity) was freshly prepared in sterile, deionized water 
shortly before each experiment. 
Treatment and toxicity testing 
For treatments, 30,000 L1 stage worms were exposed to the arsenicals for 4 h in 85 mM NaCl. 
Afterwards, worms were pelletized by centrifugation at 3,400 x g for 2 min and washed two times 
with 85 mM NaCl. For toxicity testing, the worm pellet was re-suspended in M9 buffer and 20 – 30 
worms were transferred to OP50-seeded NGM plates in triplicates. 48 h post-treatment, the total 
number of surviving worms was manually counted and scored as percentage of the original plated 
worm count. For developmental toxicity testing, their developmental stage was recorded 48 h after 
treatment, and worms reaching the L4 stage were counted to calculate the L4 score. 
Bioavailability 
To evaluate the bioavailability of the arsenicals, an aliquot of the treated worms for toxicity testing 
was taken and pelletized by centrifugation. For analysis, the worm pellets were subjected to a 
freeze/thaw cycle three times in liquid nitrogen, re-suspended in deionized water and homogenised 
by sonication (three times 20 s, 100%, with 20 s on ice between each round). For standardization, 
the protein content was determined according to Bradford29,30. Afterwards, Rh was added as 
internal standard and the worm samples were processed by microwave-assisted acid digestion (Mars 
6, CEM GmbH, Kamp-Lintfort, Germany). Arsenic content was determined by inductively coupled 
plasma tandem mass spectrometry (ICP-MS/MS; Agilent 8800 ICP-QQQ, Agilent Technologies 
Deutschland GmbH, Waldbronn, Germany) as described elsewhere14. To calculate the 
bioavailability, the arsenic concentration per pellet was normalized to the protein content.  
Metabolism studies 
For metabolism studies in L1 stage worms, incubation was carried out as described above. Exposed 
worms were pelletized, frozen in liquid nitrogen and stored at -80 °C until analysis. 
For analysis the worm pellets underwent 5 cycles of freezing in liquid nitrogen followed by 10 
minutes sonication at room temperature. Then 500 µL pure EtOH were added to the pellets and they 
were extracted by overhead shaking for 2 hours. After centrifugation at 23,000 x g for 15 min, the 
supernatant was directly used for HPLC-ICP-MS/MS-ESIMS analysis. Instrument settings and 
conditions are listed in supplementary Table S1 and Table S2. Extraction efficiency was checked by 
repeating the extraction with EtOH. Total As was determined after microwave assisted acid digestion 
in the second extract and the remaining pellet. The concentrations determined in these fractions 
were less than 1% of total As extracted in the first step. 
Statistics 
All worm experiments were carried out independently at least three times on different days. Mean 
and standard deviation (SD) were calculated from raw data and statistical analysis was performed 
with one-way analysis of variance (ANOVA) followed by Dunnett’s test. Statistically significant levels 
are indicated in the figure legends as *p < 0.05, **p < 0.01, ***p < 0.001. 
 
Figure 2: Survival and developmental effects on C. elegans after exposure (in µM) to arsenic-
containing hydrocarbons AsHC 332 and AsHC 360, arsenic-containing fatty acid AsFA 362, arsenic-
containing triacylglyceride AsTAG 912, and arsenite (iAsIII) for 4 h in the L1 larvae stage. After 48 h, 
the number of worms alive and their larvae stage were recorded. All values were compared to the 
number of seeded worms. Shown are mean values of at least three independent determinations 
+SD. One-way ANOVA followed by Dunnett’s test *p < 0.05, ***p < 0.001.  
Results and discussion 
Toxicity and bioavailability of arsenicals 
At the investigated concentration range, up to 100 µM, AsFA 362, AsTAG 912, and iAsIII affected 
neither survival nor development in C. elegans. In contrast, both AsHCs significantly affected survival 
and especially development, with the smaller compound (AsHC 332) showing greater potency than 
the larger one (AsHC 360) (Figure 2). 
Upon incubation, uptake of compounds in C. elegans can take place via their mouth, pharynx and 
consequently the intestine but also via the cuticle31,32. Because of the long hydrocarbon chain of 
the AsHCs, they might easily interact with lipophilic structures in the nematode and be taken up by 
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Figure 3: Bioavailability of arsenic-containing hydrocarbons AsHC 332 and AsHC 360, arsenic-
containing fatty acid AsFA 362, arsenic-containing triacylglyceride AsTAG 912, and arsenite (iAsIII) in 
C. elegans after exposure to 100 µM for 4 h in the L1 larvae stage normalized to the respective 
protein content. Shown are mean values of at least three independent determinations +SD. 
Bioavailability studies showed that AsTAG 912 and AsHC 332 increased the arsenic content in worms 
up to 2082 ± 601 ng As/mg protein and 1668 ± 397 ng As/mg protein, respectively (Figure 3). 
Treatments with AsHC 360 and AsFA 362 also increased the arsenic content in C. elegans, but not to 
the same extend. In general, the bioavailability of arsenic was much higher upon uptake of the 
arsenolipids compared to iAsIII. This was also observed in another in vivo model organism 
(Drosophila melanogaster). Here, after feeding with AsHCs total As concentrations were much higher 
as well33.  
Metabolism of arsenicals in C. elegans 
To further probe the metabolism of arsenolipids, arsenic speciation analysis was performed. The 
results establish that C. elegans was able to metabolize arsenolipids. In addition to the original 
incubated compound, several other peaks appeared in the ICP-MS/MS chromatogram (Figure 4). The 
identification of the main peaks was possible with high resolution molecular mass spectrometry, 
which provided the exact mass (Figure S1, table S4.). The obtained chromatograms after worm 
treatments with the two AsHCs showed the same main peak pattern. In addition to the incubated 
(original) arsenicals, their thioxo-analogues was found, as already described in in vitro studies34. 
Most of the peaks in the HPLC chromatogram, representing less polar compounds (Fig 4; RTs <1200 
s) were identified as AsFAs. The major AsFA product was the fatty acid corresponding to the 
incubated hydrocarbon in which the end of the hydrocarbon chain is oxidized to a carboxylic acid 
group. The other identified AsFAs were consistently two carbon units shorter. In the case of AsHC 
332 incubation, the products were AsFA 362, followed by AsFA 334, AsFA 306, and so on. This is 
consistent with transformation by β-oxidation, which is the common fatty acid metabolism pathway. 
This catabolic process breaks down fatty acids, such as those stored in triglycerides, to generate 
acetyl-CoA. The citric acid cycle starts with this molecule and it is important in energy production 







































































































Figure 4: Representative LC-ICP-MS/MS chromatograms of arsenic speciation analysis of L1 stage C. 
elegans after 4 h exposure to 100 µM AsHC 332 or 100 µM AsHC 360. 
After treatment with AsFA 362, also the thiolated species could be detected, but no significant 
concentrations of shorter As-containing fatty acids were observed. Interestingly, after incubation 
with AsTAG 912 no significant thioxylated, hydrolyzed or shortened metabolic products could be 
observed, but only the applied compounds as such (Figure 5). The unknown compound at RT 15.5 
minutes accounting for less than 10% of the total As could also be observed in the applied 
compound. Trace amounts of oxo- and thio-AsFA 362 could be detected in samples incubated with 









Figure 5: Representative LC- ICP-MS/MS chromatograms of arsenic speciation analysis of L1 stage C. 
elegans after 4 h exposure to 100 µM AsFA 362 and AsTAG 912.   
Conclusions 
Our novel study, is the first to provide toxicity data on species-specific effects of arsenolipids in a 
whole multicellular organism. Our novel findings demonstrate the need for the parallel use of 
speciation analysis and toxicity testing as to best characterize the toxicity of various arsenolipids. 
Despite their moderate (AsTAG) or high (AsFA) bioavailability, the former was poorly metabolized 
and the latter was only partly thiolated. In contrast, AsHCs were extensively metabolized. We 
conclude that AsTAG and AsFA themselves are non-toxic with respect to survival and development in 
the worms at the tested concentration range. Whether the substantial toxic effects induced by the 
AsHCs are caused by the parent compounds or their respective metabolites has yet to be 
determined. This study points towards a potential risk to humans related to the presence of 
arsenolipids in fish and seafood, and highlights the need for further toxicological studies of these 
compounds. 
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